ZyVersa Therapeutics, Inc., a company listed in the United States, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, made pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are not preliminary and no filing fee is required. This step is typically part of the company's preparations for upcoming shareholder meetings, where various corporate matters are voted upon. The materials filed are intended to provide additional information to shareholders beyond what was included in the original proxy statement.

ZyVersa Therapeutics, Inc., a company listed in the United States, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, made pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are not preliminary and no filing fee is required. This step is typically part of the company's preparations for upcoming shareholder meetings, where various corporate matters are voted upon. The materials filed are intended to provide additional information to shareholders beyond what was included in the original proxy statement.